Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews · Developmental, Psychosocial and Learning Problems

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated · children and adolescents aged 18 years and under diagnosed with ADHD

It is very uncertain whether the intervention changes serious adverse events Measured by: proportion of serious adverse… (very low certainty).

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
RR 1.36 [1.17, 1.57]
2 studies · 72005 participants
Very low

Intervention not reported

Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
51 studies · 162422 participants
Very low

Intervention not reported

Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
49 studies · 13978 participants
Very low

Intervention not reported

Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
37 studies · 7142 participants
Very low

Intervention not reported

Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1173 participants
Very low

Methylphenidate vs placebo or no intervention

Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) 2023 · Cochrane Headline outcomes only
RR 0.8 [0.39, 1.67]
26 studies · 3673 participants
Very low

Methylphenidate vs placebo or no intervention

Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) 2023 · Cochrane Headline outcomes only
RR 1.23 [1.11, 1.37]
35 studies · 5342 participants
Very low